[Congressional Record Volume 168, Number 133 (Saturday, August 6, 2022)]
[Senate]
[Page S4335]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 5389. Mr. MARSHALL submitted an amendment intended to be proposed 
to amendment SA 5194 proposed by Mr. Schumer to the bill H.R. 5376, to 
provide for reconciliation pursuant to title II of S. Con. Res. 14; 
which was ordered to lie on the table as follows:

        At the end of title I, add the following:

 Subtitle E--Ensuring Patient Access to Drugs and Biological Products 
                     That Treat Serious Conditions

     SEC. 14001. ENSURING PATIENT ACCESS TO DRUGS AND BIOLOGICAL 
                   PRODUCTS THAT TREAT SERIOUS CONDITIONS.

       Section 1192(e)(3) of the Social Security Act, as added by 
     section 11001, is amended by adding at the end the following 
     new subparagraphs:
       ``(D) Six protected classes.--A covered part D drug in a 
     category or class that is identified under section 1860D-
     4(b)(3)(G)(iv).
       ``(E) Breakthrough therapies.--A drug or biological product 
     designated under section 506(a) of the Federal Food, Drug, 
     and Cosmetic Act (21 U.S.C. 356(a)) as a breakthrough therapy 
     and approved under section 505 of such Act (21 U.S.C. 355) or 
     section 351 of the Public Health Service Act (42 U.S.C. 
     262).''.

     SEC. 14002. REDUCTION OF ADDITIONAL IRS FUNDING FOR 
                   ENFORCEMENT AND OPERATIONS.

       Section 10301(a)(1)(A)(i) of this Act is amended--
       (1) in subclause (II), by striking ``$45,637,400,000'' and 
     inserting ``$10,326,400,000''; and
       (2) in subclause (III), by striking ``$25,326,400,000'' and 
     inserting ``$326,400,000''.
                                 ______